Acasti announces achievement of 50% enrollment in pivotal phase 3 strive-on safety trial

Company anticipates completion of patient enrollment in the strive-on trial in late 2024 to early 2025, with potential nda submission on track for 1h calendar 2025 company anticipates completion of patient enrollment in the strive-on trial in late 2024 to early 2025, with potential nda submission on track for 1h calendar 2025
ACST Ratings Summary
ACST Quant Ranking